Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer

Yamamoto,Hirofumi; Tei,Mitsuyoshi; Uemura,Mamoru; Takemasa,Ichiro; Uemura,Yoshio; Murata,Kohei; Fukunaga,Mutsumi; Ohue,Masayuki; Ohnishi,Tadashi; Ikeda,Kimimasa; Kato,Takeshi; Okamura,Shu; Ikenaga,Masakazu; Haraguchi,Naotsugu; Nishimura,Junichi; Mizushima,Tsunekazu; Mimori,Koshi; Doki,Yuichiro; Mori,Masaki

doi:10.3892/ijo.2012.1750

Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer

Authors:
- Hirofumi Yamamoto
- Mitsuyoshi Tei
- Mamoru Uemura
- Ichiro Takemasa
- Yoshio Uemura
- Kohei Murata
- Mutsumi Fukunaga
- Masayuki Ohue
- Tadashi Ohnishi
- Kimimasa Ikeda
- Takeshi Kato
- Shu Okamura
- Masakazu Ikenaga
- Naotsugu Haraguchi
- Junichi Nishimura
- Tsunekazu Mizushima
- Koshi Mimori
- Yuichiro Doki
- Masaki Mori
View Affiliations

Affiliations: Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan, Department of Surgery, Kinki Central Hospital, Hyogo, Japan, Department of Surgery, Suita Municipal Hospital, Japan, Department of Surgery, Sakai City Hospital, Japan, Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan, Department of Surgery, NTT West Osaka Hospital, Osaka, Japan, Department of Surgery, Minoh City Hospital, Osaka, Japan, Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan, Department of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan, Department of Molecular and Cellular Biology, Division of Molecular and Surgical Oncology, Kyushu University, Medical Institute of Bioregulation, Ohita, Japan
Published online on: December 21, 2012 https://doi.org/10.3892/ijo.2012.1750
Pages: 549-555

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We previously studied hypoxic tumor cells from hepatic metastases of colorectal cancer (CRC) and determined several potential prognostic factors, including expression of ephrin-A1 (EFNA1), which was highly induced by hypoxia. Here, we further evaluated the prognostic impact of EFNA1 expression. Samples from a total of 366 CRC patients from 11 institutes were analyzed by either microarray (n=220) or quantitative reverse-transcriptase polymerase chain reaction (n=146). EFNA1 was an independent prognostic factor for CRC (p<0.05). In vitro assays revealed that loss of EFNA1 following siRNA treatment was associated with reduced proliferative activity and decreased invasion and migration of CRC cell lines. EFNA1 expression is a useful marker for predicting high risk of relapse and cancer-related death in patients who have undergone curative resection for CRC.

View Figures

View References

1.	Weitz J, Koch M, Debus J, Hohler T, Galle PR and Buchler MW: Colorectal cancer. Lancet. 365:153–165. 2005. View Article : Google Scholar
2.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin. 60:277–300. 2010.
3.	Roberts RB, Arteaga CL and Threadgill DW: Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell. 5:115–120. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Semenza GL: Hypoxia and cancer. Cancer Metastasis Rev. 26:223–224. 2007. View Article : Google Scholar
5.	Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI
6.	Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
8.	Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Vihanto MM, Plock J, Erni D, Frey BM, Frey FJ and Huynh-Do U: Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin. FASEB J. 19:1689–1691. 2005.PubMed/NCBI
10.	Yamashita T, Ohneda K, Nagano M, et al: Hypoxia-inducible transcription factor-2alpha in endothelial cells regulates tumor neovascularization through activation of ephrin A1. J Biol Chem. 283:18926–18936. 2008. View Article : Google Scholar
11.	Holzman LB, Marks RM and Dixit VM: A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol. 10:5830–5838. 1990.PubMed/NCBI
12.	Bartley TD, Hunt RW, Welcher AA, et al: B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature. 368:558–560. 1994. View Article : Google Scholar : PubMed/NCBI
13.	Brantley DM, Cheng N, Thompson EJ, et al: Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 21:7011–7026. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Pandey A, Shao H, Marks RM, Polverini PJ and Dixit VM: Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science. 268:567–569. 1995. View Article : Google Scholar : PubMed/NCBI
15.	Deroanne C, Vouret-Craviari V, Wang B and Pouyssegur J: EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway. J Cell Sci. 116:1367–1376. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Cheng N, Brantley DM, Liu H, et al: Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res. 1:2–11. 2002. View Article : Google Scholar
17.	Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL and Pasquale EB: The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene. 19:6043–6052. 2000. View Article : Google Scholar : PubMed/NCBI
18.	Abraham S, Knapp DW, Cheng L, et al: Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res. 12:353–360. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D and Chen J: Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res. 66:10315–10324. 2006. View Article : Google Scholar
20.	Noblitt LW, Bangari DS, Shukla S, et al: Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther. 11:757–766. 2004. View Article : Google Scholar
21.	Nakamura R, Kataoka H, Sato N, et al: EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci. 96:42–47. 2005. View Article : Google Scholar : PubMed/NCBI
22.	Liu DP, Wang Y, Koeffler HP and Xie D: Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK. Int J Oncol. 30:865–871. 2007.PubMed/NCBI
23.	Nasreen N, Mohammed KA, Lai Y and Antony VB: Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Cancer Lett. 258:215–222. 2007. View Article : Google Scholar : PubMed/NCBI
24.	Uemura M, Yamamoto H, Takemasa I, et al: Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer: in vivo identification from hypoxic tumor cells. Clin Cancer Res. 16:4636–4646. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Yamamoto H, Kondo M, Nakamori S, et al: JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis. Gastroenterology. 125:556–571. 2003.PubMed/NCBI
26.	Okami J, Yamamoto H, Fujiwara Y, et al: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 5:2018–2024. 1999.PubMed/NCBI
27.	Nagel S, Schmidt M, Thiede C, Huhn D and Neubauer A: Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). Nucleic Acids Res. 24:4102–4103. 1996. View Article : Google Scholar
28.	Hayashi N, Yamamoto H, Hiraoka N, et al: Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology. 34:638–650. 2001. View Article : Google Scholar : PubMed/NCBI
29.	Takemasa I, Yamamoto H, Sekimoto M, et al: Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res. 60:3043–3050. 2000.PubMed/NCBI
30.	Holm R, De Putte GV, Suo Z, Lie AK and Kristensen GB: Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis. Int J Med Sci. 5:121–126. 2008. View Article : Google Scholar : PubMed/NCBI
31.	Potla L, Boghaert ER, Armellino D, Frost P and Damle NK: Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett. 175:187–195. 2002. View Article : Google Scholar : PubMed/NCBI
32.	Brennan DJ, Jirstrom K, Kronblad A, et al: CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res. 12:6421–6431. 2006. View Article : Google Scholar
33.	Kizaka-Kondoh S, Inoue M, Harada H and Hiraoka M: Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 94:1021–1028. 2003. View Article : Google Scholar : PubMed/NCBI
34.	Noda T, Yamamoto H, Takemasa I, et al: PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection. Liver Int. 32:110–118. 2012. View Article : Google Scholar : PubMed/NCBI